Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divide.
Antiretroviral therapy (ART) is becoming available in South Africa. Demand will exceed supply; thus, difficult decisions will have to be made in allocating ART. The majority of those treated for HIV are likely to be in cities, because health infrastructure and personnel are concentrated in urban centers. We predict the epidemiological impact of drug allocation strategies (DAS) by using a spatially explicit model that links urban and rural epidemics. We parameterize our model by using data from the KwaZulu-Natal province in South Africa. We model the South African government's treatment plan from 2004-2008, and we predict the consequences of one DAS that allocates drugs only to Durban and of two DAS that allocate drugs to both urban and rural areas. All three strategies would treat 500,000 people by 2008. Not surprisingly, the Durban-only DAS would prevent the greatest number of infections (an additional 15,000 infections by 2008). However, it may have been expected that this DAS would generate the highest levels of transmitted resistance, because it concentrates ART in one location. Paradoxically, we found that this DAS would generate the lowest levels of transmitted resistance. Concentrating treatment in Durban would also avert the greatest number of AIDS-related deaths. We discuss the difference between using the principle of treatment equity versus using the principle of utilitarianism/efficiency to allocate ART. Decisions about allocating scarce drugs should consider treatment equity as well as epidemiological consequences. Notably, a Durban-only DAS would lead to new disparities in healthcare between urban and rural areas in KwaZulu-Natal.
Wilson
David P
DP
Semel Institute for Neuroscience and Human Behavior, and Department of Biomathematics, David Geffen School of Medicine, University of California, 1100 Glendon Avenue, Penthouse 2, Los Angeles, CA 90024, USA.
Kahn
James
J
Blower
Sally M
SM
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D006076:Government; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology; D006285:Health Planning / Q000941:ethics / Q000458:organization & administration; D006801:Humans; D008433:Mathematics; D008962:Models, Theoretical; D012307:Risk Factors; D012424:Rural Population; D013019:South Africa / Q000453:epidemiology; D014505:Urban Population
D044966:Anti-Retroviral Agents